Overview
Up-to-date information on this veterinary medicinal product is available on the Veterinary Medicines Information website.
Vectormune ND : EPAR - Summary for the public
English (EN)
(81.94 KB - PDF)View
български (BG)
(93.36 KB - PDF)
español (ES)
(81.97 KB - PDF)
čeština (CS)
(93.99 KB - PDF)
dansk (DA)
(83.34 KB - PDF)
Deutsch (DE)
(82.76 KB - PDF)
eesti keel (ET)
(82.18 KB - PDF)
ελληνικά (EL)
(93.76 KB - PDF)
français (FR)
(82.44 KB - PDF)
hrvatski (HR)
(92.27 KB - PDF)
íslenska (IS)
(83.29 KB - PDF)
Gaeilge (GA)
(83.57 KB - PDF)
italiano (IT)
(82.29 KB - PDF)
latviešu valoda (LV)
(94.29 KB - PDF)
lietuvių kalba (LT)
(94.03 KB - PDF)
magyar (HU)
(94.15 KB - PDF)
Malti (MT)
(95.95 KB - PDF)
Nederlands (NL)
(82.05 KB - PDF)
norsk (NO)
(82 KB - PDF)
polski (PL)
(95.62 KB - PDF)
português (PT)
(83.01 KB - PDF)
română (RO)
(94.17 KB - PDF)
slovenčina (SK)
(94.08 KB - PDF)
slovenščina (SL)
(82.27 KB - PDF)
Suomi (FI)
(81.54 KB - PDF)
svenska (SV)
(82.05 KB - PDF)
Product information
Vectormune ND : EPAR - Product Information
English (EN)
(81.49 KB - PDF)View
български (BG)
(91.78 KB - PDF)
español (ES)
(81.51 KB - PDF)
čeština (CS)
(92.48 KB - PDF)
dansk (DA)
(82.05 KB - PDF)
Deutsch (DE)
(81.72 KB - PDF)
eesti keel (ET)
(81.22 KB - PDF)
ελληνικά (EL)
(91.79 KB - PDF)
français (FR)
(81.63 KB - PDF)
hrvatski (HR)
(91.56 KB - PDF)
íslenska (IS)
(81.52 KB - PDF)
Gaeilge (GA)
(81.36 KB - PDF)
italiano (IT)
(81.76 KB - PDF)
latviešu valoda (LV)
(92.14 KB - PDF)
lietuvių kalba (LT)
(92.19 KB - PDF)
magyar (HU)
(92.76 KB - PDF)
Malti (MT)
(93.86 KB - PDF)
Nederlands (NL)
(81.15 KB - PDF)
norsk (NO)
(81.52 KB - PDF)
polski (PL)
(93.22 KB - PDF)
português (PT)
(82.53 KB - PDF)
română (RO)
(91.73 KB - PDF)
slovenčina (SK)
(81.75 KB - PDF)
slovenščina (SL)
(81.76 KB - PDF)
Suomi (FI)
(81.11 KB - PDF)
svenska (SV)
(81.47 KB - PDF)
Vectormune ND : EPAR - All Authorised presentations
English (EN)
(81.94 KB - PDF)View
български (BG)
(93.36 KB - PDF)
español (ES)
(81.97 KB - PDF)
čeština (CS)
(93.99 KB - PDF)
dansk (DA)
(83.34 KB - PDF)
Deutsch (DE)
(82.76 KB - PDF)
eesti keel (ET)
(82.18 KB - PDF)
ελληνικά (EL)
(93.76 KB - PDF)
français (FR)
(82.44 KB - PDF)
hrvatski (HR)
(92.27 KB - PDF)
íslenska (IS)
(83.29 KB - PDF)
Gaeilge (GA)
(83.57 KB - PDF)
italiano (IT)
(82.29 KB - PDF)
latviešu valoda (LV)
(94.29 KB - PDF)
lietuvių kalba (LT)
(94.03 KB - PDF)
magyar (HU)
(94.15 KB - PDF)
Malti (MT)
(95.95 KB - PDF)
Nederlands (NL)
(82.05 KB - PDF)
norsk (NO)
(82 KB - PDF)
polski (PL)
(95.62 KB - PDF)
português (PT)
(83.01 KB - PDF)
română (RO)
(94.17 KB - PDF)
slovenčina (SK)
(94.08 KB - PDF)
slovenščina (SL)
(82.27 KB - PDF)
Suomi (FI)
(81.54 KB - PDF)
svenska (SV)
(82.05 KB - PDF)
Product details
- Name of medicine
- Vectormune ND
- International non-proprietary name (INN) or common name
- Newcastle disease and Marek’s disease vaccine (live recombinant)
Pharmacotherapeutic group
- Immunologicals for aves
- Live viral vaccines
Assessment history
Vectormune ND : EPAR - Procedural steps taken and scientific information after authorisation
English (EN)
(81.94 KB - PDF)View
Vectormune ND-V-C-003829-II-0007 : EPAR - Assessment Report - Variation
English (EN)
(81.49 KB - PDF)View
CVMP post-authorisation summary of positive opinion for Vectormune ND (II/0007)
English (EN)
(68.57 KB - PDF)View
This page was last updated on